Zur Kurzanzeige

AutorGrams, Julianedc.contributor.author
Aufnahmedatum2016-03-15T10:41:50Zdc.date.accessioned
In OPARU verfügbar seit2016-03-15T10:41:50Zdc.date.available
Jahr der Erstellung2014dc.date.created
ZusammenfassungBackground: It is known for a long time, that there is an association between Diabetes mellitus and cancer diseases. Metformin as widely used antidiabetic drug could possibly have a protective effect on the development of cancer and furthermore it could be effective in therapeutic regimens. We evaluated the influence of metfomin on the AMP-activated protein kinase in non-small cell lung cancer xenografts. We examined if there is a supportive effect of metformin on the response on the monoclonal EGFR antibody Cetuximab in non-small cell lung cancer. Methods: Xenografts with non-small cell lung cancer were treated with cetuximab and metformin followed by measurement of the tumor growth. Afterwards AMPK and p70 S6k expression were determined via western blot on protein level and via rt-PCR on m-RNA level in the tumor probes. Furthermore patient data were analyzed and correlated with the tumor behavior in the xenografts. Results: Starting from 89 surgical NSCLC specimens, which were obtained from primarily diagnosed patients with early-stage tumors, 25 transplantable xenografts were established. There was no influence of metformin on tumor growth. Also there couldn`t be seen any regulation of AMPK or p70S6K in the tumors. We couldn`t show any correlation between tumor doubling time in xenografts and the overall survival, disease free survival or age of the patients. Summary: Patient derived Xenografts allow performing complex pre-clinical studies in non small cell lung cancer. Metformin didn’t influence tumor growth, the tumor response on cetuximab or regulation of AMP activated protein kinase so it doesn’t seem to have any relevance in treatment of non-small cell lung cancer.dc.description.abstract
Sprachededc.language.iso
Verbreitende StelleUniversität Ulmdc.publisher
LizenzStandarddc.rights
Link zum Lizenztexthttps://oparu.uni-ulm.de/xmlui/license_v3dc.rights.uri
SchlagwortNicht-kleinzelliges Lungenkarzinomdc.subject
SchlagwortXenograftdc.subject
DDC-SachgruppeDDC 610 / Medicine & healthdc.subject.ddc
MeSHCarcinoma, non-small-cell lung; Therapydc.subject.mesh
MeSHLung neoplasms; Therapydc.subject.mesh
MeSHProtein kinasesdc.subject.mesh
TitelRelevanz der AMP-aktivierten Proteinkinase als Biomarker in der Therapie des nicht-kleinzelligen Lungenkarzinomsdc.title
RessourcentypDissertationdc.type
DOIhttp://dx.doi.org/10.18725/OPARU-3509dc.identifier.doi
PPN424091615dc.identifier.ppn
URNhttp://nbn-resolving.de/urn:nbn:de:bsz:289-vts-93240dc.identifier.urn
GNDLungenkrebsdc.subject.gnd
GNDMetformindc.subject.gnd
FakultätMedizinische Fakultätuulm.affiliationGeneral
Datum der Freischaltung2014-12-23T08:43:49Zuulm.freischaltungVTS
Peer-Reviewneinuulm.peerReview
Signatur DruckexemplarW: W-H 13.923uulm.shelfmark
DCMI MedientypTextuulm.typeDCMI
VTS-ID9324uulm.vtsID
KategoriePublikationenuulm.category


Dateien zu dieser Ressource

Thumbnail

Das Dokument erscheint in:

Zur Kurzanzeige